J&J and Cook: Win a Little, Lose a Little
Executive SummarySome Johnson & Johnson supporters are gloating publicly over the company's recent settlement of its litigation against Cook Group Inc. for violating patents on its Palmaz-Schatz coronary stent. J&J announced in early February that it agreed to license rights to the patent to Cook in exchange for royalty payments; terms were not disclosed. J&J's release called the settlement "amicable." But the outcome is actually far from black and white.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.